Not all patients with CLL demand therapy. Irrespective of all recent advancements, the iwCLL still endorses watchful observation for people with asymptomatic disease.86 This recommendation is based on no less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,